Edition:
India

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

6.80USD
25 Sep 2020
Change (% chg)

$0.25 (+3.74%)
Prev Close
$6.55
Open
$6.56
Day's High
$6.87
Day's Low
$6.50
Volume
242,301
Avg. Vol
212,894
52-wk High
$15.43
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

CytomX Therapeutics Posts Q2 Loss Per Share Of $0.34
Friday, 7 Aug 2020 

Aug 6 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 REVENUE $16.6 MILLION VERSUS $9.0 MILLION.Q2 REVENUE ESTIMATE $48.2 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.34.Q2 EARNINGS PER SHARE VIEW $0.16 -- REFINITIV IBES DATA.  Full Article

Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration
Tuesday, 24 Mar 2020 

March 23 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS AND ASTELLAS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP PROBODY® T-CELL ENGAGING BISPECIFIC THERAPIES FOR TREATMENT OF CANCER.CO TO RECEIVE $80 MILLION UPFRONT PAYMENT AND ABILITY TO EXERCISE OPTION FOR U.S. CO-COMMERCIALIZATION RIGHTS.  Full Article

Cytomx Therapeutics Announces Appointment Of Carlos Campoy As Chief Financial Officer
Tuesday, 24 Mar 2020 

CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER.CYTOMX THERAPEUTICS - ANNOUNCED APPOINTMENT OF CARLOS CAMPOY AS SENIOR VICE PRESIDENT & CFO.  Full Article

Cytomx Therapeutics Says May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $75 Million
Friday, 28 Feb 2020 

Feb 27 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS INC - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME.  Full Article

Cytomx Therapeutics Announces Full-Year 2019 Financial Results And Provides Business Update
Friday, 28 Feb 2020 

Feb 27 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS INC 2019 (NOT QTRLY) LOSS PER SHARE $2.26.CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.  Full Article

Bristol-Myers Squibb Advances Cytomx Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 Into Randomized Cohort Expansion Of Ongoing Clinical Trial
Monday, 24 Feb 2020 

Feb 24 (Reuters) - CytomX Therapeutics Inc ::BRISTOL-MYERS SQUIBB ADVANCES CYTOMX THERAPEUTICS’ ANTI-CTLA-4 PROBODY THERAPEUTIC BMS-986249 INTO RANDOMIZED COHORT EXPANSION (PART 2A) OF ONGOING CLINICAL TRIAL.CYTOMX THERAPEUTICS INC - BRISTOL-MYERS SQUIBB ALSO ADVANCES BMS-986288 INTO A SEPARATE PHASE 1/2A CLINICAL TRIAL.CYTOMX THERAPEUTICS - ADVANCEMENT OF BMS-986249 INTO PART OF PLANNED STUDY TRIGGERS MILESTONE PAYMENT OF $10 MILLION FROM BRISTOL-MYERS SQUIBB TO CO.  Full Article

Cytomx Therapeutics Posts Q3 Revenue Of $10.7 Mln Vs $12.5 Mln
Friday, 8 Nov 2019 

Nov 7 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 REVENUE $10.7 MILLION VERSUS $12.5 MILLION.Q3 REVENUE ESTIMATE $18.1 MILLION -- REFINITIV IBES DATA.AS OF SEPTEMBER 30, 2019, CYTOMX HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $325.7 MILLION.QTRLY LOSS PER SHARE $0.52.  Full Article

CytomX Therapeutics Announces Qtrly Loss Per Share $0.64
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 REVENUE $9.0 MILLION VERSUS $21.3 MILLION.Q2 REVENUE ESTIMATE $16.6 MILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CYTOMX HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $349.1 MILLION.QTRLY LOSS PER SHARE $0.64.  Full Article

CytomX Therapeutics Reports Second Target Selection And Program Initiation With AbbVie
Tuesday, 9 Jul 2019 

July 9 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND TARGET SELECTION AND PROGRAM INITIATION WITH ABBVIE UNDER ONGOING, MULTI-PROGRAM STRATEGIC ONCOLOGY COLLABORATION.CYTOMX THERAPEUTICS INC - SECOND TARGET SELECTION BY ITS PARTNER ABBVIE UNDER COMPANIES' 2016 DISCOVERY COLLABORATION AND LICENSING AGREEMENT.CYTOMX THERAPEUTICS INC - TARGET SELECTION TRIGGERS A $10 MILLION PAYMENT TO CYTOMX FROM ABBVIE.CYTOMX THERAPEUTICS INC - ADVANCING A CLINICAL-STAGE ASSET, CX-2029, UNDER A GLOBAL CO-DEVELOPMENT AND LICENSING AGREEMENT.  Full Article

CytomX Therapeutics Says On May 22, Board Designated Dr. Sean Mccarthy, Co's Chairman & CEO, To Assume Responsibilities Of Principal Financial Officer
Wednesday, 29 May 2019 

May 29 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS - ON MAY 22, BOARD DESIGNATED DR. SEAN MCCARTHY, CO'S CHAIRMAN & CEO, TO ASSUME RESPONSIBILITIES OF PRINCIPAL FINANCIAL OFFICER.CYTOMX THERAPEUTICS - MCCARTHY'S APPOINTMENT FOLLOWS DEPARTURE OF DEBANJAN RAY, CO'S FORMER CFO WHOSE RESIGNATION BECAME EFFECTIVE ON MAY 15, 2019..CYTOMX THERAPEUTICS - BOARD DESIGNATED ROBIN KNIFSEND, TO ASSUME RESPONSIBILITIES OF PRINCIPAL ACCOUNTING OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

BRIEF-Cytomx Therapeutics Announces Preclinical Data From Anti-Ctla-4 Probody Therapeutic Programs

* CYTOMX THERAPEUTICS ANNOUNCES PRECLINICAL DATA FROM ANTI-CTLA-4 PROBODY THERAPEUTIC PROGRAMS PRESENTED BY PARTNER BRISTOL MYERS SQUIBB AT AACR ANNUAL MEETING Source text for Eikon: Further company coverage: